Group 1 - The company, 富瀚微, stated in a response to investor inquiries that it has no collaborations with photovoltaic enterprises [2]

Core Viewpoint - The company is focusing on integrating cutting-edge technologies like quantum technology with its core business in the power grid, particularly emphasizing quantum communication products [2] Group 1 - The company is developing a series of products centered around quantum communication, including quantum VPN gateways and quantum wireless security gateways [2] - The company is also working on 5G and quantum communication terminals as part of its product lineup [2]

（文章来源：证券日报） 证券日报网讯 2月11日，煌上煌发布公告称，公司已完成注册资本的工商变更登记，注册资本由 556947081元变更为559585801元，并同步修订《公司章程》，取得南昌市市场监督管理局换发的新营业 执照。 ...

证券日报网讯 2月11日，正泰电源在互动平台回答投资者提问时表示，公司新能源板块以逆变器、储能 设备为核心，依托全场景解决方案能力，为客户提供高效、可靠的产品与服务。 （文章来源：证券日报） ...

Group 1 - The company is focusing on technological development and product innovation in response to new market demands driven by AI computing power [2] - The company aims to enhance its research and development of transformer-related products to align with industry development trends [2]

（文章来源：证券日报） 证券日报网讯 2月11日，科前生物在互动平台回答投资者提问时表示，公司是一家专注于兽用生物制品 研发、生产、销售及动物防疫技术服务的生物医药企业，主要产品是非国家强制免疫猪用疫苗和禽用疫 苗。 ...

Group 1 - The company, Beijing Junzheng, stated that it does not have real-time data on the number of shareholders [2]

Core Viewpoint - The company is focusing on high-end generic drugs while accelerating the development of improved new drugs, with a specific emphasis on the antifungal field through its self-developed project XT-0043, which has shown excellent safety and efficacy in Phase II clinical trials and is moving towards Phase III trials [2] Group 1 - The company is deeply engaged in the high-end generic drug market [2] - The first self-developed improved new drug project, XT-0043, is aimed at the antifungal area [2] - XT-0043 has demonstrated outstanding safety and efficacy in Phase II clinical trials and has successfully reached clinical endpoints [2] Group 2 - The company is currently focusing on advancing the Phase III clinical trial based on the data obtained from Phase II [2]

（文章来源：证券日报） 证券日报网讯 2月11日，金春股份在互动平台回答投资者提问时表示，截至2026年1月30日公司股东人 数为10603户。 ...

证券日报网讯 2月11日，科前生物在互动平台回答投资者提问时表示，公司紧紧围绕国家饲用蛋白减量 替代重大战略，与农业微生物资源发掘与利用全国重点实验室开展紧密合作，在利用黑水虻与微生物联 合转化畜禽粪便及餐余垃圾生产昆虫蛋白领域，进行了规模化养殖工艺、自动化养殖设备的研制探索， 初步形成了一套黑水虻规模化转化农业有机废弃物的系统解决方案，为后期完善与推广应用奠定了基 础。 （文章来源：证券日报） ...